Category: Infectious Diseases

VITAMINS Trial Summary: Vit. C in Septic Shock

VITAMINS Trial Summary The VITAMINS trial aimed to determine whether the combination of vitamin C, hydrocortisone, and thiamine is more effective than hydrocortisone alone in expediting the resolution of septic shock. The trial included 216 patients with septic shock and compared the duration of time alive and free of vasopressor administration over 7 days between […]

WRAP-IT Trial: Utilizing Antibiotic-Eluting Envelopes to Reduce Infections After Cardiac Device Implantation

WRAP-IT Trial Summary Infections following the placement of cardiac implantable electronic devices (CIEDs) can lead to significant morbidity and mortality. Although preoperative antibiotics are a standard prophylactic strategy, evidence for other preventive approaches is limited. The WRAP-IT trial sought to examine the efficacy and safety of an absorbable, antibiotic-eluting envelope in reducing CIED-associated infections. The […]

ANTHARTIC Trial: Preventing VAP after CA

2019 ANTHARTIC TRIAL M Prevention of early Ventilator-Associated Pneumonia after cardiac arrest Multicentre, randomised, double-blind, placebo-controlled Objective: To investigate whether in post out-of-hospital cardiac arrest (OOHCA) patients treated with targeted temperature management, does the use of empirical antibiotics prevent early ventilator-associated pneumonia. 194 patients Inclusion criteria: Patients ≥ 18 years of age hospitalized in the […]

ANDROMEDA SHOCK Trial: Resuscitation in Septic Shock

ANDROMEDA-SHOCK: Effect of a Resuscitation Strategy Targeting Peripheral Perfusion Status vs Serum Lactate Levels in Septic Shock Multicenter, randomized trial conducted at 28 intensive care units in 5 countries 424 patients with septic shock were randomized to to a step-by-step resuscitation protocol aimed at: 000 normalizing capillary refill time (n=212) normalizing or decreasing lactate levels […]

AMBITION Trial: Liposomal amphotericin B in Cryptococcal meningitis

2022 AMBITION TRIAL Single-dose liposomal amphotericin B treatment for cryptococcal meningitis Open-label, phase 3, non inferiority, randomized controlled trial M Objective: To determine the efficacy and safety of single high dose (10mg/kg) of liposomal amphotericin B in HIV-positive adults with cryptococcal meningitis 844 patients Inclusion criteria: HIV-positive adults > 18 years who had first episode […]

SINGLE Trial: Dolutegravir in HIV

2013 SINGLE TRIAL M Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection double-blind, randomized controlled trial 844 Objective: To assess the safety & efficacy of dolutegravir at a dose of 50 mg plus a fixed-dose combination of abacavir-lamivudine, as compared with fixed-dose efavirenz-tenofovir DF-emtricitabine for the treatment of HIV-1 patients Inclusion criteria: Patients aged […]

AMAZES Trial Summary: Azithromycin in Asthma

2017 AMAZES TRIAL Azithromycin in asthma exacerbations Multicenter, double-blind, placebo controlled parallel group trial M Objective: In adult patients with symptomatic asthma who are currently using an inhaled corticosteroid or a long-acting bronchodilator, does oral azithromycin decrease the frequency of asthma exacerbations? 420 patients Inclusion criteria: ≥18 years of age with clinically defined asthma; symptomatic […]

AIDA-WP2 Trial Summary: Fosfomycin or Nitrofurantoin in UTI

2018 AIDA-WP2 Effect of 5-Day nitrofurantoin vs single-dose fosfomycin on M clinical resolution of uncomplicated lower urinary tract infection in women Multinational, open-label, analyst-blinded, randomized clinical trial Objective: To compare the clinical and microbiologic efficacy of nitrofurantoin and fosfomycin in women with uncomplicated cystitis (eppley). 513 patients Inclusion criteria: Women ≥18 years of age with […]

ACTT-2 Trial Summary: Baricitinib + Remdesivir in Covid-19

2020 ACTT-2 TRIAL Baricitinib plus Remdesivir for Hospitalized Adults with Covid-1 Double-blind, randomized, placebo-controlled trial M Objective: To compare the clinical efficacy of combination of baricitinib plus remdesivir with remdesivir alone among hospitalized adults with laboratory-confirmed Covid-19. 1033 patients Patients with lab-confirmed SARS-CoV-2 infection with illness of any duration and atleast one of the following: […]